Ajinomoto Co., Ltd.

Kohichi Fujita

Tsuyoshi Kobayashi

Takashi Yamamoto

Yukio Iino

Kenji Takehana

Ariko Kodaira

Yasuhiro Tanaka

Takashi Tsuji

Manabu Suzuki

Masahiro Murata

Tadakiyo Nakagawa

Tatsuhiro Yamada

Yuka Ikenoue

Tomoyuki Tagami

Hideki Matsumoto

Masayuki Sugiki

Kazuyuki Sagi

Akira Chiba

Takashi Kayahara

Shunji Takehana

Kuniya Sakurai

Yoshitomo Chujo

Shunsuke Fukuda

Kazumi Tashiro

Yoshitomo Chujoh

Syunsuke Fukuda

A pharmaceutical composition containing a heterocyclic compound of the formula (I) wherein each symbol is as defined in the specification, an isomer thereof, a solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient has a superior TNF-&#x3b1; production suppressing action. Accordingly, it is useful for the prophylaxis or treatment of various diseases caused by abnormal production of TNF-&#x3b1;.

Heterocyclic compounds

The present invention provides an AP-1 activation inhibitor, NF-kappa B activation inhibitor, inflammatory cytokine production inhibitor, matrix metalloprotease production inhibitor, inflammatory cell adhesion molecule expression inhibitor, anti-inflammatory agent, antirheumatic agent, immunosuppressant, cancer metastasis inhibitor, remedy for arteriosclerosis and antiviral agent which contain the benzene derivative of the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. 

Benzene derivatives and pharmaceutical use thereof

The inventive subject matter relates to compounds, pharmaceutical compositions, and kits containing a heterocyclic compound represented by the formula (I) wherein R is an alkyl group optionally having substituent(s) etc., X is an amino group optionally having substituent(s), Yand Yare nitrogen atoms etc., an isomer or solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient.

An amidinophenylpyruvic acid derivative of the following formula, analogs thereof and pharmaceutically acceptable salts thereof have an excellent antagonistic effect against activated blood coagulation factor VII.

Amidinophenylpyruvic acid derivatives

The present invention provides an AP-1 activation inhibitor, NF-kappa B activation inhibitor, inflammatory cytokine production inhibitor, matrix metalloprotease production inhibitor, inflammatory cell adhesion molecule expression inhibitor, anti-inflammatory agent, antirheumatic agent, immunosuppressant, cancer metastasis inhibitor, remedy for arteriosclerosis and antiviral agent which contain the benzene derivative of the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

The present invention discloses biscyclopropanecarboxamide compounds and pharmaceutically acceptable salts thereof; and also NF-kappa B activation inhibitors, Inflammatory cytokine production inhibitors, matrix metalloprotease production inhibitors, inflammatory cell adhesion molecules incidence inhibitors, antiinflammatory agents, antirheumatic agents, immunosuppressive agents, cancerous metastasis inhibitors or antiviral agents each containing such a compound as the active ingredient.

Biscyclopropanecarboxamide compounds and pharmaceutical use thereof

Growing community of inventors

Kawasaki, Japan

Kohichi Fujita